Abstract
Background: Vaccine-induced neutralizing antibodies are key in combating the coronavirus disease 2019 (COVID-19) pandemic. However, delays of boost immunization due to limited availability of vaccines may leave individuals vulnerable to infection and prolonged or severe disease courses. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC)-B.1.1.7 (United Kingdom), B.1.351 (South Africa), and P.1 (Brazil)-may exacerbate this issue, as the latter two are able to evade control by antibodies.
Methods: We assessed humoral and T-cell responses against SARS-CoV-2 wild-type (WT), VOC, and endemic human coronaviruses (hCoVs) that were induced after single and double vaccination with BNT162b2.
Results: Despite readily detectable immunoglobulin G (IgG) against the receptor-binding domain of the SARS-CoV-2 S protein at day 14 after a single vaccination, inhibition of SARS-CoV-2 S-driven host cell entry was weak and particularly low for the B.1.351 variant. Frequencies of SARS-CoV-2 WT and VOC-specific T cells were low in many vaccinees after application of a single dose and influenced by immunity against endemic hCoV. The second vaccination significantly boosted T-cell frequencies reactive for WT and B.1.1.7 and B.1.351 variants.
Conclusions: These results call into question whether neutralizing antibodies significantly contribute to protection against COVID-19 upon single vaccination and suggest that cellular immunity is central for the early defenses against COVID-19.
Keywords: SARS-CoV-2; T cells; antibodies; vaccination.
【저자키워드】 antibodies, SARS-CoV-2, vaccination, T cells, 【초록키워드】 COVID-19, coronavirus disease, neutralizing antibody, IgG, Coronavirus disease 2019, Vaccine, coronavirus, vaccination, pandemic, Immunity, S protein, Neutralizing antibodies, VoC, B.1.351, T cells, T-cell Response, Infection, variants of concern, severe acute respiratory syndrome Coronavirus, immunization, BNT162b2, T cell, Immunoglobulin G, South Africa, Receptor-binding domain, Immunoglobulin, cellular immunity, B.1.1.7, P.1, HCoV, T-cell, respiratory, United Kingdom, T-cell responses, boost, single dose, SARS-CoV-2 S protein, Endemic, Frequency, severe disease, B.1.351 variants, humoral, host cell, acute respiratory syndrome, frequencies, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, second vaccination, B.1.351 variant, individual, wild-type, HCoVs, Defense, courses, single vaccination, endemic human coronaviruses, SARS-CoV-2 WT, reactive, vaccinee, combating, significantly, detectable, question, contribute, the receptor-binding domain, evade, exacerbate, endemic human coronavirus, the SARS-CoV-2, 【제목키워드】 Human, coronavirus 2, response, Against,